## Drug of Choice for Type 2 Diabetes Monotherapy **Key Point:** Metformin is the first-line agent for type 2 diabetes mellitus monotherapy in patients without contraindications, as per ADA, EASD, and Indian guidelines (RSSDI). ### Why Metformin Is Preferred 1. **Mechanism & Benefits** - Biguanide that reduces hepatic glucose production and improves insulin sensitivity - Does NOT cause hypoglycemia when used alone - Associated with modest weight loss or weight neutrality - Cardiovascular and renal protective effects 2. **Evidence Base** - Landmark UKPDS trial demonstrated superior cardiovascular outcomes with metformin - Reduces all-cause mortality and MI risk in overweight patients - First-line recommendation in all major guidelines (ADA 2023, EASD, RSSDI) 3. **Safety Profile** - Well-tolerated with GI side effects being most common (mitigated by extended-release formulation) - No weight gain - Contraindicated only in eGFR <30 mL/min/1.73m² (use with caution 30–45) ### Comparison with Other Options | Agent | Mechanism | Hypoglycemia Risk | Weight Effect | First-Line? | |-------|-----------|-------------------|---------------|-------------| | **Metformin** | ↓ HGP, ↑ insulin sensitivity | No | Neutral/loss | **YES** | | Glibenclamide | ↑ Insulin secretion | **High** | Gain | No | | Acarbose | ↓ Carbohydrate absorption | No | Neutral | No (adjunct) | | Pioglitazone | ↑ Insulin sensitivity (PPARγ) | No | **Significant gain** | No (second-line) | **High-Yield:** Metformin is the ONLY agent recommended as true monotherapy first-line in all major guidelines. All other agents are either second-line, adjunctive, or reserved for specific scenarios. **Clinical Pearl:** Even in patients with mild renal impairment (eGFR 45–60), metformin can be continued with dose adjustment and monitoring. Absolute contraindication is eGFR <30 or acute kidney injury. [cite:KD Tripathi 8e Ch 27]
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.